作者 | 谢思燕1，郑忠信2，焦营营2，李珍2单位 | 1.桂林医学院第二附属医院检验科，2.南方医科大学南方医院血液科前言伯基特淋巴瘤(Burkit ...

safety and efficacy data from an investigator-sponsored trial evaluating the combination of Orca-T with allogeneic CD19/CD22-CAR-T cells in patients with high-risk B-cell acute lymphoblastic ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that new clinical data will be presented in three oral ...

HCL variant is also called splenic B-cell lymphoma with prominent nucleoli ... 104 HCL antigens such as CD19, CD20, CD22, CD79b, and CD123 represent appealing targets for antibody–drug ...

Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a ...

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of ...

在这项研究中，Diorio和她的团队分析了两名儿童、两名青少年和一名年轻成人，这些患者在接受靶向CD19或CD22的CAR-T细胞输注治疗B-ALL后，出现了严重 ...

Interested parties can access the live webcasts for the conferences in the Investors section of CARGO’s website under News & Events. The webcast replays will be available after the conclusion of the ...

B-cell therapy (also called B-cell depletion therapy) is a treatment for people with multiple sclerosis (MS). It targets certain cells -- called B cells -- that can damage nerve fibers in your ...

Researchers previously reported that CAR-T may lead to complications known as immune effector cell-associated ... of either ...